Ontology highlight
ABSTRACT: Purpose
To compare Thais' health-related quality of life (HRQOL) and severity grading, efficacy and safety in daily-life-affected benign essential blepharospasm (BEB) patients at baseline and after Botulinum toxin type A (BTX-A) treatment.Design
Prospective-observational study.Participants
BEB patients with Jankovic rating scale (JRS) at least 3 in both severity and frequency graded from 14 institutes nationwide were included from August 2020 to June 2021.Methods
Demographic data, HRQOL evaluated by the Thai version of EQ-5D-5L and NEI-VFQ-25 questionnaires, and severity grading score evaluated by Jankovic rating scale (JRS) at baseline, 1, and 3 months after the treatment were collected. The impact of the BTX-A injections and their complications were recorded.Results
184 daily-life-affected BEB patients were enrolled; 159 patients (86.4%) had complete data with a mean age of 61.40±10.09 years. About 88.05% were female, and 10.1% were newly diagnosed. Most of the patients had bilateral involvement (96.9%) and 12.6% had history of BEB-related accident. After BTX-A treatment, HRQOL improved significantly in 4 dimensions of EQ-5D-5L, except self-care. The EQ_VAS (mean±SD) was 64.54±19.27, 75.13±15.37, 73.8±15.85 (p<0.001) and EQ-5D-5L utility score was 0.748±0.23, 0.824±0.19 and 0.807±0.19 at baseline, 1, 3 months after treatment, respectively. From NEI-VFQ-25, HRQOL also improved in all dimensions, except eye pain. The JRS improved in all patients. Self-reported minor adverse events were 22.6%, which mostly resolved within the first month.Conclusion
Daily-life-affected BEB impacted HRQOL in most dimensions from both generic and visual-specific questionnaires. BTX-A treatment not only decreased disease severity, but also improved quality of life.
SUBMITTER: Hirunwiwatkul P
PROVIDER: S-EPMC10016646 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature

Hirunwiwatkul Parima P Supawatjariyakul Wajamon W Jariyakosol Supharat S Apinyawasisuk Supanut S Sriratanaban Jiruth J Chongpison Yuda Y Jagota Priya P Aui-Aree Nipat N Witthayaweerasak Juthamat J Setthawatcharawanich Suwanna S Kitthaweesin Kitthisak K Chirapapaisan Niphon N Chaimongkoltrakul Piyawadee P Laowanapiban Poramaet P Hansapinyo Linda L Panpitpat Suthida S Kurathong Sireedhorn S Nimworaphan Jirat J Thitiwichienlert Suntaree S Vanikieti Kavin K Samipak Narong N Srimanan Worapot W Mekhasingharak Nattapong N Chaitanuwong Pareena P
PloS one 20230315 3
<h4>Purpose</h4>To compare Thais' health-related quality of life (HRQOL) and severity grading, efficacy and safety in daily-life-affected benign essential blepharospasm (BEB) patients at baseline and after Botulinum toxin type A (BTX-A) treatment.<h4>Design</h4>Prospective-observational study.<h4>Participants</h4>BEB patients with Jankovic rating scale (JRS) at least 3 in both severity and frequency graded from 14 institutes nationwide were included from August 2020 to June 2021.<h4>Methods</h4> ...[more]